Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-919373 in Paroxysmal Atrial Fibrillation
NCT02156076Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2014
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of BMS-919373 in Atrial fibrillation (AFib), sponsored by Bristol Myers Squibb. Started Jul 2014; status: terminated.
02
Drugs
BMS-919373
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT02156076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02156076.